Ambulero

Ambulero, Inc. is a pioneering startup that emerged from the University of Miami, specializing in cell and gene therapies aimed at combating vascular diseases. Vascular diseases affect the blood vessels and can lead to severe health issues, including heart attacks and strokes. Ambulero's innovative approach focuses on using advanced therapies to repair tissues damaged by these diseases.

The company has developed two main treatment methods. The first involves using stromal cells, which are a type of cell that supports tissue repair. These cells are engineered to express a molecule called E-selectin, which enhances their ability to heal damaged tissues. Ambulero refers to these as "supercharged stromal cells" because they have shown exceptional results in animal studies. The second method is a gene therapy approach that directly delivers the E-selectin molecule to injured tissues using established gene therapy vectors, which are tools used to deliver genetic material into cells.

Ambulero operates in the biotechnology and healthcare market, focusing on developing regenerative products that offer new ways to treat vascular diseases. Their clients include medical institutions, research organizations, and potentially patients suffering from vascular conditions.

The business model of Ambulero revolves around research and development (R&D) of these therapies, followed by clinical trials to ensure their safety and effectiveness. Once approved, the company plans to commercialize these therapies, either by selling them directly to healthcare providers or through partnerships with larger pharmaceutical companies. This model allows Ambulero to generate revenue through product sales, licensing agreements, and potentially milestone payments from partners.

Ambulero is also part of the 2023-2024 cohort of the NYU Stern School of Business Endless Frontier Labs (EFL) small business incubator. This program supports science and technology startups, helping them grow and succeed. Being part of this incubator provides Ambulero with valuable resources, mentorship, and networking opportunities.

In summary, Ambulero is at the forefront of developing cutting-edge therapies for vascular diseases, leveraging advanced cell and gene therapy techniques to offer new hope for patients.

Keywords: cell therapy, gene therapy, vascular disease, stromal cells, E-selectin, regenerative medicine, biotechnology, healthcare, R&D, NYU Stern EFL.